Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 21;37(11):e87.
doi: 10.3346/jkms.2022.37.e87.

Volumetric Splenomegaly in Patients With Polycythemia Vera

Myung-Won Lee  1 , Sang-Hoon Yeon  1 , Hyewon Ryu  1 , Ik-Chan Song  1 , Hyo-Jin Lee  1 , Hwan-Jung Yun  1 , Seon Young Kim  2 , Jeong Eun Lee  3 , Kyung Sook Shin  3 , Deog-Yeon Jo  4
Affiliations

Volumetric Splenomegaly in Patients With Polycythemia Vera

Myung-Won Lee et al. J Korean Med Sci. .

Abstract

Background: Non-palpable splenomegaly in patients with polycythemia vera (PV) has seldom been addressed. In this retrospective study, we evaluated non-palpable, volumetric splenomegaly defined based on age- and body surface area (BSA)-matched criteria in patients with PV diagnosed according to the 2016 World Health Organization diagnostic criteria.

Methods: Patients with PV who underwent abdominal computed tomography (CT) and who had palpable splenomegaly at diagnosis from January 1991 to December 2020 at Chungnam National University Hospital were enrolled. The spleen volume of each patient was determined by volumetric analysis of abdominal CT and adjusted for the patient's age and BSA. Then the degree of splenomegaly was classified as no splenomegaly, borderline volumetric splenomegaly, overt volumetric splenomegaly, or palpable splenomegaly.

Results: Of the 87 PV patients enrolled, 15 (17.2%) had no splenomegaly, whereas 17 (19.5%), 45 (51.7%), and 10 (11.5%) had borderline volumetric, overt volumetric, and palpable splenomegaly, respectively. The degree of splenomegaly did not affect the cumulative incidence of thrombotic vascular events (10-year incidence: 7.7%, 0%, 22.3%, and 50.7%, respectively, P = 0.414). By contrast, splenomegaly tended to adversely affect myelofibrotic transformation (10-year cumulative incidence: 0%, 0%, 7.1%, and 30.3%, respectively, P = 0.062). Moreover, the cumulative incidence of myelofibrotic transformation was significantly higher in patients with overt volumetric or palpable splenomegaly than those with no or borderline volumetric splenomegaly (10-year incidence: 0% vs. 10.3%, respectively; 15-year incidence: 0% vs. 26.3%, respectively, P = 0.020). Overall survival (OS) differed among patients with different degrees of splenomegaly (15-year OS: 100%, 78.6%, 71.7%, and 51.9%, respectively, P = 0.021).

Conclusion: The degree of splenomegaly, including volumetric splenomegaly, based on age- and BSA-matched reference spleen volumes at diagnosis reflects disease progression in PV patients. Therefore, volumetric splenomegaly should be evaluated at the time of diagnosis and taken into consideration when predicting the prognosis of patients with PV.

Keywords: Computed Tomography; Myelofibrosis; Polycythemia Vera; Spleen; Splenomegaly; Survival.

PubMed Disclaimer

Conflict of interest statement

The authors have no potential conflicts of interest to disclose.

Figures

Fig. 1
Fig. 1. Incidence of splenomegaly over time in patients with polycythemia vera.
Fig. 2
Fig. 2. Cumulative incidence of myelofibrotic transformation according to the degree of splenomegaly in patients with polycythemia vera.
Fig. 3
Fig. 3. Overall survival according to the degree of splenomegaly in patients with polycythemia vera.
See this image and copyright information in PMC

References

    1. Spivak JL. Polycythemia vera. Curr Treat Options Oncol. 2018;19(2):12. - PubMed
    1. Mesa R. Myeloproliferative disorder-associated massive splenomegaly. Clin Adv Hematol Oncol. 2008;6(4):278. - PubMed
    1. Song MK, Park BB, Uhm JE. Understanding splenomegaly in myelofibrosis: association with molecular pathogenesis. Int J Mol Sci. 2018;19(3):E898. - PMC - PubMed
    1. Hehlmann R, Jahn M, Baumann B, Köpcke W. Essential thrombocythemia. Clinical characteristics and course of 61 cases. Cancer. 1988;61(12):2487–2496. - PubMed
    1. Jantunen R, Juvonen E, Ikkala E, Oksanen K, Anttila P, Hormila P, et al. Essential thrombocythemia at diagnosis: causes of diagnostic evaluation and presence of positive diagnostic findings. Ann Hematol. 1998;77(3):101–106. - PubMed

LinkOut - more resources